Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study

Trial Profile

Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder; Urge incontinence
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Jul 2015 Planned End Date changed from 1 May 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 06 Jul 2015 Planned primary completion date changed from 1 May 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 28 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top